Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHINOOK THERAPEUTICS, INC.ADRO · Entity 110632 | Chief Medical Officer | September 12, 2018 | September 14, 2018 |
| Caribou Biosciences, Inc.CRBU · Entity 6445 | Director | February 20, 2026 | February 20, 2026 |
| Harpoon Therapeutics, Inc.HARP · Entity 11424 | Chief Medical Officer | January 28, 2022 | February 01, 2022 |
| Zymeworks BC Inc.ZYME · Entity 12038 | Director | May 06, 2021 | May 07, 2021 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | December 21, 2022 | December 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHINOOK THERAPEUTICS, INC.
Report date September 12, 2018 · Filed September 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 173,720 |
Ending reported balance
After 2018-09-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-09-12 · Grant · Acquired 87,200 · Balance 176,748 F1: Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of September 12, 2018. Row 2 · 2018-09-13 · Sale · Disposed 3,028 · Balance 173,720 F2: The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of September 12, 2018.
F2: The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Caribou Biosciences, Inc.
Report date February 20, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2036-02-19 | Direct | 45,000 |
Reported balance
After 2026-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 45,000 · Balance 45,000 F1: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.
Harpoon Therapeutics, Inc.
Report date January 28, 2022 · Filed February 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.03 · Expires 2032-01-27 | Direct | 155,000 |
Reported balance
After 2022-01-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-28 · Grant · Acquired 155,000 · Balance 155,000 F1: 1/48th of the total stock option will vest and become exercisable monthly on the same day of each month following the vesting commencement date of January 28, 2022, subject to the continuing employment of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the total stock option will vest and become exercisable monthly on the same day of each month following the vesting commencement date of January 28, 2022, subject to the continuing employment of the Reporting Person on each vesting date.
Zymeworks BC Inc.
Report date May 06, 2021 · Filed May 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.49 · Expires 2031-05-05 | Direct | 9,000 |
Reported balance
After 2021-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-06 · Grant · Acquired 9,000 · Balance 9,000 F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021.
Zymeworks Inc.
Report date December 21, 2022 · Filed December 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.75 · Expires 2032-12-20 | Direct | 25,000 |
Reported balance
After 2022-12-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-21 · Grant · Acquired 25,000 · Balance 25,000 F1: Stock options vest on date of next annual general meeting following grant date of December 21, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on date of next annual general meeting following grant date of December 21, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2026 Filed Feb 20, 2026 17:28 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 45,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001683811-26-000002 · wk-form4_1771626484.xml · derivative · entry 1 Sacks Natalie · CIK 0001683811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2036-02-19 F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 20:16 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 40,500 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001683811-25-000003 · wk-form4_1740186979.xml · derivative · entry 1 Sacks Natalie · CIK 0001683811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,500 Underlying: Common Stock · 40,500 shares Expires 2035-02-19 F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2026, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 17:08 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 39,500 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001628280-24-006412 · wk-form4_1708639705.xml · derivative · entry 1 Sacks Natalie · CIK 0001683811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,500 Underlying: Common Stock · 39,500 shares Expires 2034-02-19 F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2025, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 17:12 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 21,500 | $0.00 Strike: $6.12 | $0.00 |
DisclosureSEC source: 0001619856-23-000024 · wf-form4_167719030244436.xml · derivative · entry 1 Sacks Natalie · CIK 0001683811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-02-20 F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 21, 2024, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 19:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $8.75 | $0.00 |
DisclosureSEC source: 0000899243-22-039327 · doc4.xml · derivative · entry 1 Sacks Natalie · CIK 0001683811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-12-20 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 21, 2022. Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 16:07 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantEmployee Stock Option (right to buy) · Derivative | 155,000 | $0.00 Strike: $5.03 | $0.00 |
DisclosureSEC source: 0001209191-22-005890 · doc4.xml · derivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: 1/48th of the total stock option will vest and become exercisable monthly on the same day of each month following the vesting commencement date of January 28, 2022, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 17:38 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 27,500 | $0.00 Strike: $15.16 | $0.00 |
DisclosureSEC source: 0001209191-21-070823 · doc4.xml · derivative · entry 1 Sacks Natalie · CIK 0001683811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2031-12-19 F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on December 20, 2022, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document |
| November 11, 2021 Filed Nov 15, 2021 16:03 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantEmployee Stock Option (right to buy) · Derivative | 155,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001209191-21-064441 · doc4.xml · derivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2031-11-11 F1 · derivative.exercise_date: Fifty percent of the stock option shall be fully vested and exercisable on the first anniversary of the vesting commencement date, November 11, 2022, and thereafter twenty-five percent of the stock option shall vest on each May 11, 2023, and November 11, 2023. Read SEC document |
| May 06, 2021 Filed May 7, 2021 20:45 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $29.49 | $0.00 |
DisclosureSEC source: 0000899243-21-018765 · doc4.xml · derivative · entry 1 Sacks Natalie · CIK 0001683811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2031-05-05 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of May 6, 2021. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 20:00 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantEmployee Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $18.66 | $0.00 |
DisclosureSEC source: 0001209191-21-006313 · doc4.xml · derivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/48th of the shares subject to the option on February 28, 2021, and thereafter vests as to 1/48th of the shares in equal monthly installments at the end of each month, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| May 18, 2020 Filed May 20, 2020 18:34 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,522 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-031019 · doc4.xml · derivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,625 Underlying: Common Stock · 1,522 shares Expires 2028-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on November 16, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| May 18, 2020 Filed May 20, 2020 18:34 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 1,522 | $14.77 | $22,478.57 |
DisclosureSEC source: 0001209191-20-031019 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $14.70 to $14.90 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 18, 2020 Filed May 20, 2020 18:34 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 1,522 | $2.12 | $3,226.64 |
DisclosureSEC source: 0001209191-20-031019 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2020 Filed May 12, 2020 06:32 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $35.49 | $0.00 |
DisclosureSEC source: 0000899243-20-012778 · doc4.xml · derivative · entry 1 Sacks Natalie · CIK 0001683811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2030-05-07 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of May 8, 2020. Read SEC document |
| May 01, 2020 Filed May 5, 2020 16:35 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,826 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-027143 · doc4.xml · derivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,926 Underlying: Common Stock · 5,826 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 1, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| May 01, 2020 Filed May 5, 2020 16:35 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 5,826 | $12.07 | $70,301.18 |
DisclosureSEC source: 0001209191-20-027143 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $11.81 to $12.31 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 01, 2020 Filed May 5, 2020 16:35 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 5,826 | $2.12 | $12,351.12 |
DisclosureSEC source: 0001209191-20-027143 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2020 Filed Apr 17, 2020 19:10 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,021 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-024947 · doc4.xml · derivative · entry 6 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,147 Underlying: Common Stock · 1,021 shares Expires 2028-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on November 16, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| April 17, 2020 Filed Apr 17, 2020 19:10 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 1,021 | $12.08 | $12,330.11 |
DisclosureSEC source: 0001209191-20-024947 · doc4.xml · nonDerivative · entry 4 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $12.00 to $12.15 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 17, 2020 Filed Apr 17, 2020 19:10 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 1,021 | $2.12 | $2,164.52 |
DisclosureSEC source: 0001209191-20-024947 · doc4.xml · nonDerivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 16, 2020 Filed Apr 17, 2020 19:10 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-024947 · doc4.xml · derivative · entry 5 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,168 Underlying: Common Stock · 500 shares Expires 2028-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on November 16, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| April 16, 2020 Filed Apr 17, 2020 19:10 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 500 | $12.00 | $6,000.00 |
DisclosureSEC source: 0001209191-20-024947 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 16, 2020 Filed Apr 17, 2020 19:10 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 500 | $2.12 | $1,060.00 |
DisclosureSEC source: 0001209191-20-024947 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 16:48 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,556 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-024489 · doc4.xml · derivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,752 Underlying: Common Stock · 4,556 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 1, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 16:48 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 4,556 | $12.06 | $54,959.03 |
DisclosureSEC source: 0001209191-20-024489 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $12.00 to $12.21 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 16:48 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 4,556 | $2.12 | $9,658.72 |
DisclosureSEC source: 0001209191-20-024489 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 18:10 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 570 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-023954 · doc4.xml · derivative · entry 6 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,308 Underlying: Common Stock · 570 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 1, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 18:10 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 570 | $12.00 | $6,840.00 |
DisclosureSEC source: 0001209191-20-023954 · doc4.xml · nonDerivative · entry 4 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 07, 2020 Filed Apr 8, 2020 18:10 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 570 | $2.12 | $1,208.40 |
DisclosureSEC source: 0001209191-20-023954 · doc4.xml · nonDerivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 18:10 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 700 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-023954 · doc4.xml · derivative · entry 5 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,878 Underlying: Common Stock · 700 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 1, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 18:10 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 700 | $12.00 | $8,400.98 |
DisclosureSEC source: 0001209191-20-023954 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $12.00 to $12.01 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 06, 2020 Filed Apr 8, 2020 18:10 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 700 | $2.12 | $1,484.00 |
DisclosureSEC source: 0001209191-20-023954 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 17:28 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,520 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-020052 · doc4.xml · derivative · entry 6 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,668 Underlying: Common Stock · 1,520 shares Expires 2028-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on November 16, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 17:28 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 1,520 | $12.00 | $18,240.00 |
DisclosureSEC source: 0001209191-20-020052 · doc4.xml · nonDerivative · entry 4 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 17:28 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 1,520 | $2.12 | $3,222.40 |
DisclosureSEC source: 0001209191-20-020052 · doc4.xml · nonDerivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 17:28 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-020052 · doc4.xml · derivative · entry 5 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,188 Underlying: Common Stock · 1 shares Expires 2028-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on November 16, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 17:28 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 1 | $12.00 | $12.00 |
DisclosureSEC source: 0001209191-20-020052 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 17:28 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 1 | $2.12 | $2.12 |
DisclosureSEC source: 0001209191-20-020052 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:31 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,826 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-015855 · doc4.xml · derivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,578 Underlying: Common Stock · 5,826 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 1, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:31 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 5,826 | $14.68 | $85,525.68 |
DisclosureSEC source: 0001209191-20-015855 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $14.55 to $15.37 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:31 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 5,826 | $2.12 | $12,351.12 |
DisclosureSEC source: 0001209191-20-015855 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 17:11 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,521 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-011190 · doc4.xml · derivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,189 Underlying: Common Stock · 1,521 shares Expires 2028-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on November 16, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 17:11 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 1,521 | $15.00 | $22,815.00 |
DisclosureSEC source: 0001209191-20-011190 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 17:11 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 1,521 | $2.12 | $3,224.52 |
DisclosureSEC source: 0001209191-20-011190 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 20:11 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,826 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-006706 · doc4.xml · derivative · entry 4 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,404 Underlying: Common Stock · 5,826 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 1, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 20:11 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 5,826 | $13.90 | $81,006.45 |
DisclosureSEC source: 0001209191-20-006706 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $13.72 to $14.27 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 20:11 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 5,826 | $2.12 | $12,351.12 |
DisclosureSEC source: 0001209191-20-006706 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 20:11 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | GrantEmployee Stock Option (right to buy) · Derivative | 75,440 | $0.00 Strike: $13.29 | $0.00 |
DisclosureSEC source: 0001209191-20-006706 · doc4.xml · derivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,440 Underlying: Common Stock · 75,440 shares Expires 2030-01-30 F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/48th of the shares subject to the option on February 29, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments at the end of each month, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 20:05 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,521 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-004374 · doc4.xml · derivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,710 Underlying: Common Stock · 1,521 shares Expires 2028-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on November 16, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 20:05 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 1,521 | $14.94 | $22,724.96 |
DisclosureSEC source: 0001209191-20-004374 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $14.90 to $15.00 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.